Theme

Multidisciplinary Real-World cases of allergic patients that require antihistamine (AH) use.

Methods

Multidisciplinary Real-World cases that required AH use. Cases should be coupled with evidence from the literature.  Any discussion concerning off-label use should be considered an expert opinion only. The target audience for this contest are physicians who treat patients with conditions requiring AHs.

The cases presented may include any kind of patient, irrespective of concomitant diseases or medications, who need to be treated with antihistamines for conditions such as allergic rhinitis or rhino-conjunctivitis and urticaria /angioedema, as well as less common but challenging conditions such as urticarial vasculitis and pruritus skin conditions. Special circumstances or populations, such as elderly, and/or poly-medicated patients, renal/hepatic impairment, or any other that may concur should be described.

Jury panel of the challenge

An expert panel with three allergy KOLs will select and choose the three final winning cases among those received before 30^th September 2020.

Members of the panel

• Ignacio J. Ansotegui, Head of the Department of Allergy and Immunology at Hospital Quironsalud Bizkaia in Bilbao, Spain
• Martin K. Church., Honorary Professor of Immunopharmacology, Charité-Universitätsmedizin, Berlin, Germany and Emeritus Professor of Immunopharmacology of the School of Medicine of the University of Southampton, UK.
• Pablo Rodríguez del Rio, Allergist, Senior Consultant. MD, PhD, at the Universitary Hospital Niño Jesús, Madrid, Spain

The panel members will evaluate the cases taking in account the following issues:

• Complete clinical description of the case, triggers, aggravating and/or improving factors as well as impact on the quality of life
• Treatment options, and what treatment(s) were previously used
• Has immunotherapy been used as a treatment option. And if so, when, for how long, and which allergens
• When were antihistamines prescribed and how the treatment modified the course of the disease.
• Did any adverse events occur? If yes, describe.
• Particularities of the presented case, lessons to be learned, and main conclusions.
• Cases should follow ethical and good practice procedures.
• Cases previously published will not be accepted.

The panel will discuss the information presented and the use of AHs. During a one-day panel meeting each member of the panel will present 3 selected cases, followed by a group discussion, after which a final consensus vote on the cases will be conducted to select 3 cases as the winners.  The defined prizes are:

1^st place »     Participation in EAACI 2021, including a European flight in Tourist class or            equivalent, 3 hotel nights, and registration in the Congress

2nd place » Participation in EAACI 2021, including 3 hotel nights and registration in Congress

3rd place »   Registration in EAACI 2021 or equivalent.

The panel will also review other cases and select an additional X cases for inclusion in a future publication. Should a case selected for publication require any additional information, it will be required by the panel.

Authors (and co-authors if any) agree to the cases being published, will be included as authors of this publication and give up their copyrights for this purpose. The final publication will be published for free download in this website.

FAES FARMA reserves the right to declare this challenge void in case none of the cases comply with the requirements aforementioned.

Format

Maximum 1000 words and 1 table/figure
Should include a 25 words brief summary explaining why the case is relevant
Up to 5 references

DATA TO BE UPLOADED:

• Name and e-mail address of the doctor/clinician treating the patient, who will be considered Author of the case and contact person. If coauthors want to be listed, please include here too.
• Cases will be anonymized and then assigned to the judge members for the shake of impartiality.
• Patient details:
  • age (years), sex (male, female), medical history of interest for the case, location of the condition, condition present since
• Impact of condition:
• Impact on: daily activities (yes/no); professional life (yes/no), social life (yes/no), self-image (yes/no), sleep disturbance (yes/no), or any other considered relevant.
• if answered yes, give details

• Baseline, Treatment Information:
  • Previous treatment: dose, frequency, period used for
  • Current treatment: dose, frequency, period used for
  • If immunotherapy was/is used, include type, period used for
  • Why oral antihistamine was chosen for this patient/condition
  • Medication used during the observation period may be presented in a table as shown below

• End of treatment:
• Condition has improved*

*1 = strongly disagree, 2 = Disagree, 3 = Neutral, 4 = agree, 5 = strongly agree

• Impact of condition:
  • Impact on: daily activities (yes/no); professional life (yes/no), social life (yes/no), self-image (yes/no), sleep disturbance (yes/no)
  • if answered yes, give details
• Have adverse events occurred? (yes/no)
• If yes, please give details
• Use of photographic documentation should have permission from the patient to use these photographs for the report/publication. Permission not to be included but must be available if needed.